PD-L1 和 PD-1 的翻译后调控：联合免疫治疗的机制和机会。
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.
机构信息
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
出版信息
Semin Cancer Biol. 2022 Oct;85:246-252. doi: 10.1016/j.semcancer.2021.04.002. Epub 2021 Apr 5.
Antibodies targeting programmed cell death protein 1 (PD-1) or its ligand programmed death-ligand 1 (PD-L1) are profoundly changing the methods to treat cancers with long-term clinical benefits. Unlike conventional methods that directly target tumor cells, PD-1/PD-L1 blockade exerts anti-tumor effects largely through reactivating or normalizing cytotoxic T lymphocyte in the tumor microenvironment to combat cancer cells. However, only a small fraction of cancer patients responds well to PD-1/PD-L1 blockade and clinical outcomes have reached a bottleneck without substantial advances. Therefore, better understanding the molecular mechanisms underlying how PD-1/PD-L1 expression is regulated will provide new insights to improve the efficacy of current anti-PD-1/PD-L1 therapy. Here, we provide an update of current progress of PD-L1 and PD-1 post-translational regulations and highlight the mechanism-based combination therapy strategies for a better treatment of human cancer.
针对程序性细胞死亡蛋白 1（PD-1）或其配体程序性死亡配体 1（PD-L1）的抗体正在深刻改变治疗癌症的方法，为患者带来长期的临床获益。与直接针对肿瘤细胞的传统方法不同，PD-1/PD-L1 阻断主要通过在肿瘤微环境中重新激活或使细胞毒性 T 淋巴细胞正常化来发挥抗肿瘤作用，从而对抗癌细胞。然而，只有一小部分癌症患者对 PD-1/PD-L1 阻断反应良好，并且在没有实质性进展的情况下，临床结果已经达到了瓶颈。因此，更好地了解 PD-1/PD-L1 表达如何受到调控的分子机制将为提高当前抗 PD-1/PD-L1 治疗的疗效提供新的见解。在这里，我们提供 PD-L1 和 PD-1 翻译后调控的最新进展，并强调基于机制的联合治疗策略，以更好地治疗人类癌症。
Zotero 插件